Related Experiment Video
Updated: Oct 2, 2025
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation
Geng Song1, Fei-Fei Zhang1, Huai-Dong Cheng1
1Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Objectives:
The study evaluated the efficacy of thalidomide in prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP).
Methods:
In this study, patients treated with camrelizumab plus thalidomide or camrelizumab alone were included. The occurrences, onset time, severity of RCCEP and the adverse effect of thalidomide were analysed.
Results:
A total of 19 patients were enrolled. The incidence of RCCEP in thalidomide group (2/9, 22.2%) was significantly lower than that in camrelizumab group (8/10, 80%). The median onset time of RCCEP was 5 weeks and 4 weeks respectively. The adverse events of thalidomide were mild, and no treatment-associated interruption was observed.
Conclusions:
Thalidomide showed a promising in prevention of the RCCEP in patients receiving camrelizumab therapy with an acceptable safety profile.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:15Drugs that Stabilize Microtubules